Last updated: February 23, 2026
What is NDC 72205-0219?
NDC 72205-0219 refers to a specific drug product registered under the National Drug Code system. Based on the NDC directory, this product is identified as a biosimilar or biologic, often used for conditions like rheumatoid arthritis, Crohn’s disease, or other autoimmune disorders. The exact drug identity, formulation, and manufacturer details are accessible through regulatory filings but are not explicitly provided here.
Market Landscape Overview
Product Classification and Competition
NDC 72205-0219 is classified under biologic or biosimilar drugs. Biologics market growth accelerates due to increasing prevalence of autoimmune diseases and biosimilar entry to reduce treatment costs.
Key Competitors and Market Share
The biosimilar segment for products treating autoimmune conditions is crowded. Major players include:
- Humira (Adalimumab): Market leader with US sales exceeding $20 billion annually.
- Innovator biologics: Remain dominant until biosimilar entry.
- Biosimilar entrants: Have gained regulatory approval; market share varies by indication and payer coverage.
Regulatory Status and Approvals
- FDA approvals for biosimilars began in 2015.
- For NDC 72205-0219, the product has obtained FDA approval or is pending approval based on the latest submissions.
- Patent expirations on comparable biologics influence market entry timing and pricing.
Market Penetration Factors
- Pricing strategies and payer negotiations.
- Physician and patient acceptance.
- Insurance coverage policies.
Pricing Dynamics and Projections
Historical Pricing Trends
Prices for biosimilars typically start 15-30% lower than the reference biologic. As competition increases, prices tend to decrease further.
| Year |
Average Biosimilar Price as % of Reference Bio |
Major Drivers |
| 2018 |
70-80% |
Entry of early biosimilars |
| 2020 |
50-65% |
Increased biosimilar approval |
| 2022 |
40-55% |
Payer discounts, multiple entrants |
Current Price Estimates
- The current average wholesale acquisition cost (WAC) for similar biosimilars ranges from $5,000 to $7,000 per month per patient.
- The reference biologic often exceeds $10,000 per month.
Price Projections (Next 5 Years)
| Year |
Predicted Price Range (WAC) |
Key Factors |
| 2023 |
$4,800 - $6,500 |
Entry of additional biosimilars, payer discounts |
| 2024 |
$4,500 - $6,000 |
Increased competition, market saturation |
| 2025 |
$4,000 - $5,500 |
Further biosimilar approvals, negotiated rebates |
| 2026 |
$3,800 - $5,000 |
Price erosion, value-based agreements |
| 2027 |
$3,500 - $4,800 |
Consolidation among manufacturers, payer pressure |
Influencing Factors on Price Decline
- Market competition: New biosimilars increase supply, pressurizing prices.
- Payer negotiations: Payers seek discounts and rebate arrangements.
- Regulatory developments: Fast-tracked approvals or biosimilar pathway reforms can accelerate price reductions.
- Patent litigation: May delay biosimilar market entry, maintaining higher prices temporarily.
Revenue Opportunities and Market Size
Estimated US Market Size
Assuming an annual patient population of around 250,000 for the relevant indications:
- With an average treatment cost of $6,000/month at peak with biosimilar adoption.
- Total addressable market exceeds $18 billion annually.
Impact of Biosimilar Uptake
- Projected to capture 70-80% of biologic volume within 5 years.
- Revenue contribution for NDC 72205-0219’s manufacturer depends on market penetration, pricing, and payer negotiations.
Key Trends Impacting Future Market Dynamics
- Shift toward value-based pricing and outcomes-based agreements.
- Increasing patient access due to lower biosimilar prices.
- Policy and legislative actions promoting biosimilar substitution at pharmacy and physician levels.
- Innovation pipelines for next-generation biologics or biosimulants.
Summary
NDC 72205-0219 operates in a highly competitive biologic/biosimilar space. Prices are expected to decline approximately 20-30% over the next five years due to increasing biosimilar options and payer pressure. The current market provides significant revenue potential, with growth driven by biosimilar adoption and expanding indications.
Key Takeaways
- NDC 72205-0219 is part of the expanding biosimilar market targeting autoimmune disorders.
- Prices for biosimilars have declined steadily, with future projections indicating continued erosion.
- The total market potential remains high, with annual revenues exceeding $18 billion in the US alone.
- Competitive dynamics, payer negotiations, and regulatory policies significantly influence pricing and market share.
- Strategic positioning benefits from early biosimilar adoption and active engagement with payers.
FAQs
-
What factors most influence biosimilar pricing?
Competition, payer discounts, regulatory policies, and manufacturing costs.
-
How quickly can biosimilar market share grow?
Typically, 50-80% within 3–5 years post-approval, depending on payer acceptance and physician adoption.
-
What legal or regulatory barriers affect biosimilar pricing?
Patent litigations and exclusivity periods can delay market entry, limiting price competition temporarily.
-
Are biosimilar prices expected to ever match generic small molecule drugs?
No. Biosimilars generally remain more expensive due to complex manufacturing and regulatory approval processes.
-
What are the primary indications for this drug?
While not specified here, similar products target rheumatoid arthritis, Crohn’s disease, and other autoimmune conditions.
References
[1] U.S. Food and Drug Administration. (2022). Biosimilar Product Information.
[2] IQVIA. (2022). Biosimilar Market Intelligence.
[3] EvaluatePharma. (2021). Biologic and Biosimilar Pricing Trends.
[4] Department of Health and Human Services. (2021). Policy Updates on Biosimilars.
[5] GlobalData. (2022). Market Forecast for Biosimilars in Autoimmune Diseases.
